Concord Biotech
Ticker > Company >

Concord Biotech share price

Concord Biotech Ltd.

NSE: CONCORDBIO BSE: 543960 SECTOR: Pharmaceuticals & Drugs  1.06 L   127   26

1269.35
-18.60 (-1.44%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 1290.75

Today's Low

₹ 1263.15

52 Week High

₹ 1979.2

52 Week Low

₹ 987.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 13279.46 Cr.

Enterprise Value

₹ 13270.18 Cr.

No. of Shares

10.46 Cr.

P/E

50.44

P/B

6.57

Face Value

₹ 1

Div. Yield

0.59 %

Book Value (TTM)

₹  193.06

CASH

₹ 9.28 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

44.08 %

EPS (TTM)

₹  25.17

Sales Growth

-12.08%

ROE

13.74 %

ROCE

18.38%

Profit Growth

-29.41 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 20Indices.

NIFTY500

Nifty 500
23145.05
  -207.100000000002 (-0.886856242358847%)

NFT500HEALTH

Nifty500 Healthcare Index
21155.7
  -265.899999999998 (-1.24127049333382%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
21082.6
  -243.900000000001 (-1.14364757461375%)

NFTMIDSML40050:50

Nifty MidSmallcap400 50:50
20533.6
  -245.950000000001 (-1.18361562209%)

NFTSMALL500

Nifty Smallcap 500
20248.5
  -259.599999999999 (-1.26584130172955%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
18318.85
  -193.450000000001 (-1.04498090458777%)

NIFTYSMALLCAP250

Nifty Smallcap 250
17863.75
  -237.25 (-1.31070106623944%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
16391.25
  -161.5 (-0.975668695533971%)

NFT500EQUAL

Nifty 500 Equal Weight
14809.95
  -161.949999999999 (-1.08169303829173%)

NIFTYTOTALMCAP

NIFTY Total Market
13055.7
  -118.549999999999 (-0.899861472190067%)

SHARIAH500

Nifty500 Shariah
6899.25
  -54.6499999999996 (-0.785889932268213%)

BSE HC

Bse Healthcare
49821.23
  -643.18 (-1.27452198489986%)

SMLCAP

Bse SmallCap
46825.31
  -1050.74000000001 (-2.19470904554575%)

BSE500

Bse 500
36196.43
  -321.849999999999 (-0.881339427815331%)

MSL400

Bse 400 MidSmallCap Index
12580.64
  -148.75 (-1.16855560242871%)

S&P MIDSMLCAP

Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

BSE1000

Bse 1000
10827.76
  -96.9799999999996 (-0.887709913462464%)

ALLCAP

Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SHA500

Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

SML250

Bse 250 SmallCap Index
7024.38
  -99.3400000000001 (-1.39449613404233%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-12.08%
3 Year7.34%
5 Year11.33%

Profit Growth

1 Year-29.41%
3 Year3.4%
5 Year2.27%

ROE%

1 Year13.74%
3 Year19.24%
5 Year18.9%

ROCE %

1 Year18.38%
3 Year25.66%
5 Year25.08%

Debt/Equity

0

Price to Cash Flow

50.34

Interest Cover Ratio

454.929

CFO/PAT (5 Yr. Avg.)

0.903936354478878

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2026 44.08 0.00
Mar 2026 44.08 0.00
Dec 2025 44.08 0.00
Sep 2025 44.08 0.00
Jun 2025 44.08 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 0.3811 Cr.
  • Company has been maintaining healthy ROCE of 25.6617333333333% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 454.929.
  • The Company has been maintaining an effective average operating margins of 39.9503242592893% in the last 5 years.
  • Company has a healthy liquidity position with current ratio of 7.4455.

 Limitations

  • The company has shown a poor profit growth of 3.40212432006346% for the Past 3 years.
  • The company has shown a poor revenue growth of 7.33681424695278% for the Past 3 years.
  • The company is trading at a high PE of 50.44.
  • The company is trading at a high EV/EBITDA of 31.005.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Net Sales 429.88 203.99 247.06 278.13 325.89
Total Expenditure 239.46 142.59 156.52 175.91 203.51
Operating Profit 190.42 61.4 90.54 102.22 122.38
Other Income 9.38 13.68 13.43 10.08 15.54
Interest 0.1 0.06 0.06 0.06 0.06
Depreciation 14.62 17.78 18.39 18.67 19.49
Exceptional Items 0 0 0 -3.28 0
Profit Before Tax 185.09 57.24 85.52 90.3 118.38
Tax 43.16 14.67 22.62 22.51 28.36
Profit After Tax 141.94 42.57 62.9 67.78 90.02
Adjusted EPS (Rs) 13.57 4.07 6.01 6.48 8.6

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 712.93 853.17 1016.94 1200.09 1055.07
Total Expenditure 439.01 504.59 584.75 693.24 678
Operating Profit 273.93 348.58 432.19 506.84 377.08
Other Income 23.42 35.31 33.78 44.45 52.73
Interest 6.13 9.8 3.18 1.04 0.77
Depreciation 50.05 54.03 53.59 54.37 74.33
Exceptional Items 0 0 0 0 -3.28
Profit Before Tax 241.16 320.05 409.19 495.88 351.43
Tax 62.59 81.93 104.46 122.91 88.17
Net Profit 178.57 238.13 304.73 372.96 263.27
Adjusted EPS (Rs.) 17.07 22.76 29.13 35.65 25.17

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 9.51 10.46 10.46 10.46 10.46
Total Reserves 1097.65 1281.52 1514.79 1802.18 2009.29
Borrowings 31.25 6.24 0 0 0
Other N/C liabilities 212.23 25.9 31.91 37.47 49.54
Current liabilities 151.89 190.53 142.16 184.06 167.24
Total Liabilities 1502.53 1514.65 1699.32 2034.18 2236.54
Assets
Net Block 572.98 592.98 575.32 794.69 786.41
Capital WIP 74.16 172.7 211.48 50.13 78.16
Intangible WIP 0 0 0 0.53 1.17
Investments 0.92 0.79 0.67 18.65 85.63
Loans & Advances 220.99 11.61 12.81 12.01 32.68
Other N/C Assets 0.82 8.87 2.81 22.93 7.28
Current Assets 632.67 727.7 896.23 1135.24 1245.22
Total Assets 1502.53 1514.65 1699.32 2034.18 2236.54
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations 241.16 320.05 409.19 495.88 351.43
Adjustment 49.16 48.51 40.8 28.82 38.93
Changes in Assets & Liabilities -22.06 -52.29 -81.18 -170.76 -29.12
Tax Paid -60.78 -70.28 -103.35 -109.42 -97.47
Operating Cash Flow 207.47 246 265.47 244.52 263.78
Investing Cash Flow -111.79 -157.95 -154.61 -159.99 -142.28
Financing Cash Flow -100.16 -85.22 -99.21 -98.77 -114.51
Net Cash Flow -4.48 2.83 11.64 -14.24 6.98

Corporate Actions

Investors Details

PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
promoters 44.08 44.08 44.08 44.08 44.08
ankur sudhir vaid 0.56 - - - 0.56
manju vaid 9.55 - - - 9.55
sonal kumra 0.07 - - - 0.07
sudhir kumar vaid - 28.84 28.84 28.84 28.84
sudman consultants llp 4.54 4.54 4.54 4.54 4.54
vaid megha ankur 0.52 - - - 0.52
ankur sudhir vaid - 0.56 0.56 0.56 -
manju vaid - 9.55 9.55 9.55 -
sonal kumra - 0.07 0.07 0.07 -
vaid megha ankur - 0.52 0.52 0.52 -
sudhir vaid 28.84 - - - -
PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
investors 55.92 55.92 55.92 55.92 55.92
1575773 ontario inc 2.00 2.00 2.00 2.00 2.00
aryaman jhunjhunwala disc... - - - 8.03 8.03
aryavir jhunjhunwala disc... 8.03 8.03 8.03 8.03 8.03
axis max life insurance l... 1.52 1.52 1.52 1.52 1.34
chanakya corporate servic... - 1.11 1.11 1.11 1.11
dsp small cap fund - - 1.74 1.75 1.75
government pension fund g... 2.66 2.74 2.99 2.99 2.95
llp 0.13 0.14 0.13 0.15 0.14
nishtha jhunjhunwaladiscr... 8.03 8.03 8.03 8.03 8.03
ohm stock broker private ... - - - 1.05 1.05
ravindra raichand dharams... 1.20 1.20 1.20 1.20 1.20
tata aia life insurance c... 1.55 1.95 2.02 1.91 2.48
amal parikh 1.93 1.93 1.74 - -
aryaman jhunjhunwaladiscr... 8.03 - 8.03 - -
aryaman jhunjhunwala dis... - 8.03 - - -
chanakya corporate servic... 1.11 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2026
Annual Report 2024

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q3FY25
Concall Q3FY24
Concall Q2FY24
Concall Q1FY25
Concall Q1FY24
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY26
Presentation Q4FY24
Presentation Q3FY24
Presentation Q1FY24

Company News

 No Latest News available for this company.Report us

Concord Biotech Stock Price Analysis and Quick Research Report. Is Concord Biotech an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Concord Biotech. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Concord Biotech has a PE ratio of 50.4073117424995 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Concord Biotech has ROA of 12.3289% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Concord Biotech has a Current ratio of 7.4455.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Concord Biotech has a ROE of 13.739%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Concord Biotech has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Concord Biotech has reported revenue growth of -12.0838% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Concord Biotech for the current financial year is 35.7393862593134%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Concord Biotech is Rs 7.55 and the yield is 0.5953%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Concord Biotech is Rs 25.165. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Concord Biotech in Ticker for free. Also, one can get the intrinsic value of Concord Biotech by using Valuation Calculators, which are available with a Finology ONE subscription. 

Concord Biotech FAQs

Q1. What is Concord Biotech share price today?
Ans: The current share price of Concord Biotech is Rs 1268.5.

Q2. What is the market capitalisation of Concord Biotech?
Ans: Concord Biotech has a market capitalisation of Rs 13270.5654774 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Concord Biotech?
Ans: The PE ratio of Concord Biotech is 50.4073117424995 and the P/B ratio of Concord Biotech is 6.57039412005408, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Concord Biotech share?
Ans: The 52-week high share price of Concord Biotech is Rs 1980, and the 52-week low share price of Concord Biotech is Rs 987.

Q5. Does Concord Biotech pay dividends?
Ans: Currently, Concord Biotech pays dividends. Dividend yield of Concord Biotech is around 0.5953%.

Q6. What are the face value and book value of Concord Biotech shares?
Ans: The face value of Concord Biotech shares is Rs 1, while the book value per share of Concord Biotech is around Rs 193.063. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Concord Biotech?
Ans: Concord Biotech has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Concord Biotech?
Ans: The ROE of Concord Biotech is 13.739% and ROCE of Concord Biotech is 18.3786%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Concord Biotech a good buy for the long term?
Ans: The Concord Biotech long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Concord Biotech undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Concord Biotech appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Concord Biotech’s financials?
Ans: You can review Concord Biotech’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Concord Biotech

Concord Biotech Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Concord Biotech Ltd. is a renowned biotechnology company that specializes in the development and manufacturing of fermentation-based products. With a strong focus on research and development, the company has established itself as a leader in the biopharmaceutical and nutraceutical industries. Founded in the year XXXX, Concord Biotech has consistently delivered innovative solutions to its customers.

Concord Biotech Ltd. Stock Analysis – Share Price

The share price of Concord Biotech Ltd. reflects the market's perception of the company's future prospects. As a long-term stock investor, understanding the factors that influence the share price is crucial. At our website, you can monitor and analyze the historical share price movements of Concord Biotech Ltd. using our pre-built screening tools.

Concord Biotech Ltd. Stock Analysis – Balance Sheet

The balance sheet of Concord Biotech Ltd. provides insights into the company's financial position and its ability to meet its obligations. As a long-term investor, analyzing the balance sheet is essential to understand the company's assets, liabilities, and equity. At our website, you can access the company's annual reports for a comprehensive review of its balance sheet. Our premium features, such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, enable fair value calculation for informed investment decisions.

Concord Biotech Ltd. Stock Analysis – Annual Report

The annual report of Concord Biotech Ltd. provides comprehensive information about the company's financial performance, business strategies, and future outlook. At our website, you can download the annual reports of Concord Biotech Ltd. for a detailed analysis and better understanding of the company's operations.

Concord Biotech Ltd. Stock Analysis – Dividend

Dividends are an important consideration for long-term investors as they provide a regular income stream. Concord Biotech Ltd. has a consistent track record of rewarding its shareholders through dividends. By analyzing the company's dividend history, investors can assess its financial stability and the potential for future dividend payouts.

Concord Biotech Ltd. Stock Analysis – Quarterly Result

Analyzing the quarterly results of Concord Biotech Ltd. allows investors to gauge the company's financial performance on a regular basis. Our website provides access to the quarterly reports of Concord Biotech Ltd., enabling investors to stay updated with the latest financial results and make informed investment decisions.

Concord Biotech Ltd. Stock Analysis – Stock Price

The stock price of Concord Biotech Ltd. is influenced by various factors, including market sentiment, industry trends, and the company's financial performance. By monitoring the stock price movements and trends, investors can identify potential buying or selling opportunities. Our website provides a price chart for Concord Biotech Ltd., allowing investors to visualize the historical stock price data.

Concord Biotech Ltd. Stock Analysis – Price Chart

Our website offers a price chart feature that allows investors to analyze the historical stock price movements of Concord Biotech Ltd. This tool enables users to identify trends, patterns, and potential price levels for informed decision-making.

Concord Biotech Ltd. Stock Analysis – News

Keeping track of the latest news and developments related to Concord Biotech Ltd. is essential for investors. Our website provides a dedicated news section where users can access the latest news articles and updates about the company. Staying informed about industry trends, regulatory changes, and company-specific news is crucial for effective stock analysis.

Concord Biotech Ltd. Stock Analysis – Concall and Transcripts

Concalls (conference calls) are an important source of information for investors as they provide insights into a company's performance, strategies, and future outlook. At our website, you can access the concall transcripts of Concord Biotech Ltd., allowing you to stay updated with the management's discussions and analysis of the company's operations.

Concord Biotech Ltd. Stock Analysis – Investor Presentations

Investor presentations play a significant role in understanding a company's business model, growth plans, and strategic initiatives. Concord Biotech Ltd. provides investor presentations that offer valuable insights into the company's operations and opportunities. By analyzing these presentations, investors can gain a deeper understanding of Concord Biotech Ltd.'s growth prospects and investment potential.

Concord Biotech Ltd. Stock Analysis – Promoters and Shareholders

The promoters and major shareholders of Concord Biotech Ltd. play a crucial role in shaping the company's direction and decision-making. Understanding the key stakeholders can provide insights into their commitment to the company's success. At our website, you can access information about the promoters and major shareholders of Concord Biotech Ltd., helping you evaluate their influence on the company's operations and future plans.

In conclusion, Concord Biotech Ltd. presents an attractive opportunity for long-term stock investors seeking to analyze the company's performance and prospects. Our website offers various tools and resources, including pre-built screening tools, annual reports, concall transcripts, investor presentations, and premium features like fair value calculation using DCF analysis, BVPS analysis, earnings multiple approach, and DuPont analysis. Stay informed and make informed investment decisions with our comprehensive stock analysis tools and information on Concord Biotech Ltd. 

Concord Biotech Balance Sheet Overview

Concord Biotech's Growing Reserves

Analyzing Concord Biotech's balance sheet data, it is evident that the company has significantly augmented its total reserves, from Rs. 760.57 Cr in March 2020 to a robust Rs. 1,514.79 Cr by March 2024. This growth trajectory underlines the company's ability to bolster its financial stability over the years.

Concord Biotech's Debt Management

A remarkable aspect of Concord Biotech's financial health is its effective debt management. The company has methodically reduced its borrowings from Rs. 35.53 Cr in March 2020 to an impressive zero by March 2024. This indicates a strategic focus on minimizing leverage and enhancing equity financing.

Concord Biotech's Asset Allocation

On the assets front, Concord Biotech has shown a consistent increase in its current assets, from Rs. 646.76 Cr in March 2020 to Rs. 896.23 Cr by March 2024. This growth in current assets, alongside investments in Net Block and Capital WIP, underscores the company’s commitment to expanding its operational capacities and asset base.

This data represents an analysis for the Standalone Balance Sheet of Concord Biotech. It offers crucial insights for investors looking at stock screening processes, thereby facilitating informed investment decisions in sectors that Concord Biotech operates within.

Read More
X